Clinical outcomes of Hydrus Microstent implantation for open-angle glaucoma: Results from a large academic center.

Purpose: To assess the clinical outcomes of Hydrus Microstent implantation with cataract extraction for the treatment of open angle glaucoma (OAG) over a maximum of 4 years.

Design: Retrospective, single-center, single-arm, longitudinal cohort study.

Subjects: 308 patients (464 eyes) with OAG who underwent Hydrus Microstent implantation with cataract extraction between February 2019 and December 2021, followed for a median (interquartile range, IQR) of 2.

Cellular component transfer between photoreceptor cells of the retina.

Photoreceptor transplantation is a potential therapeutic strategy for degenerative retinal diseases. Studies on mechanisms contributing to retinal regeneration and vision repair identified cellular components transfer (CCT) as playing a role, in addition to somatic augmentation (referred to as "cell replacement" in this paper). In CCT, donor photoreceptors shuttle proteins, RNA, and mitochondria to host photoreceptors through intercellular connections.

Cell-cell interactions between transplanted retinal organoid cells and recipient tissues.

The transplantation of human organoid-derived retinal cells is being studied as a potentially viable strategy to treat vision loss due to retinal degeneration. Experiments in animal models have demonstrated the feasibility of organoid-derived photoreceptor transplantation in various recipient contexts. In some cases, vision repair has been shown.